CRISPR-mediated transcriptional activation with synthetic guide RNA.


Journal

Journal of biotechnology
ISSN: 1873-4863
Titre abrégé: J Biotechnol
Pays: Netherlands
ID NLM: 8411927

Informations de publication

Date de publication:
10 Aug 2020
Historique:
received: 10 10 2019
revised: 03 04 2020
accepted: 07 05 2020
pubmed: 30 5 2020
medline: 13 1 2021
entrez: 30 5 2020
Statut: ppublish

Résumé

The CRISPR-Cas9 system has been adapted for transcriptional activation (CRISPRa) and several second-generation CRISPRa systems (including VPR, SunTag, and SAM) have been developed to recruit different transcriptional activators to a deactivated Cas9, which is guided to a transcriptional start site via base complementarity with a target guide RNA. Multiple studies have shown the benefit of CRISPRa using plasmid or lentiviral expressed guide RNA, but the use of synthetic guide RNA has not been reported. Here we demonstrate the effective use of synthetic guide RNA for gene activation via CRISPRa. CRISPRa crRNA may be used with a canonical tracrRNA using the VPR or SunTag activation systems or with an extended tracrRNA containing an aptamer sequence for the SAM system. Transcriptional activation with synthetic crRNA:tracrRNA is comparable to activation achieved with expression vectors and combining several crRNA sequences targeting the same gene can enhance transcriptional activation. The use of synthetic crRNA is also ideal for simultaneous activation of multiple genes or use with dCas9-VPR mRNA when viral transduction is not feasible. Here, we perform a proof-of-principle arrayed screen using a CRISPRa crRNA library consisting of 153 cytokine receptor targets to identify regulators of IL-6 cytokine secretion. Together, these results demonstrate the suitability of synthetic CRISPRa guide RNA for high throughput, arrayed screening applications which allow for more complex phenotypic readouts to complement viability and drug resistance assays typically used in a pooled screening format.

Identifiants

pubmed: 32470463
pii: S0168-1656(20)30125-5
doi: 10.1016/j.jbiotec.2020.05.005
pii:
doi:

Substances chimiques

Aptamers, Nucleotide 0
RNA, Guide 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-35

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors report no declarations of interest.

Auteurs

Žaklina Strezoska (Ž)

Horizon Discovery, Lafayette 80026, United States.

Sarah Michelle Dickerson (SM)

Horizon Discovery, Lafayette 80026, United States.

Elena Maksimova (E)

Horizon Discovery, Lafayette 80026, United States.

Eldon Chou (E)

Horizon Discovery, Lafayette 80026, United States.

Maren Mayer Gross (MM)

Horizon Discovery, Lafayette 80026, United States.

Kevin Hemphill (K)

Horizon Discovery, Lafayette 80026, United States.

Travis Hardcastle (T)

Horizon Discovery, Lafayette 80026, United States.

Matthew Perkett (M)

Horizon Discovery, Lafayette 80026, United States.

Jesse Stombaugh (J)

Horizon Discovery, Lafayette 80026, United States.

Galen W Miller (GW)

Horizon Discovery, Lafayette 80026, United States.

Emily M Anderson (EM)

Horizon Discovery, Lafayette 80026, United States.

Annaleen Vermeulen (A)

Horizon Discovery, Lafayette 80026, United States.

Anja van Brabant Smith (AVB)

Horizon Discovery, Lafayette 80026, United States. Electronic address: anja.smith@horizondiscovery.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH